Epitra 750 Tablet contains Levetiracetam 750mg, an antiepileptic agent indicated for the treatment of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby stabilizing neuronal activity and reducing seizure frequency. Epitra 750 is prescribed as adjunctive therapy or monotherapy depending on the clinical scenario and patient response. The tablet should be administered orally, with dosage individualized based on patient age, renal function, and seizure type. Common adverse effects include somnolence, dizziness, fatigue, and behavioral changes such as irritability or mood swings, which generally diminish with continued use. Caution is advised in patients with renal impairment, and dose adjustments may be necessary. Epitra 750 should be used under strict medical supervision, with regular monitoring to assess therapeutic efficacy and tolerability. Abrupt discontinuation is discouraged due to the risk of increased seizure frequency. This medication is contraindicated in patients with known hypersensitivity to Levetiracetam or any of its excipients. Epitra 750 offers a well-tolerated and effective option for seizure management, improving quality of life for individuals with epilepsy.